223 related articles for article (PubMed ID: 32344660)
1. AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors.
Rangel N; Rondon-Lagos M; Annaratone L; Aristizábal-Pachon AF; Cassoni P; Sapino A; Castellano I
Cells; 2020 Apr; 9(4):. PubMed ID: 32344660
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
3. AR-PDEF pathway promotes tumour proliferation and upregulates MYC-mediated gene transcription by promoting MAD1 degradation in ER-negative breast cancer.
Cao L; Xu C; Xiang G; Liu F; Liu X; Li C; Liu J; Meng Q; Jiao J; Niu Y
Mol Cancer; 2018 Sep; 17(1):136. PubMed ID: 30217192
[TBL] [Abstract][Full Text] [Related]
4. The role of the AR/ER ratio in ER-positive breast cancer patients.
Rangel N; Rondon-Lagos M; Annaratone L; Osella-Abate S; Metovic J; Mano MP; Bertero L; Cassoni P; Sapino A; Castellano I
Endocr Relat Cancer; 2018 Mar; 25(3):163-172. PubMed ID: 29386247
[TBL] [Abstract][Full Text] [Related]
5. AR pathway activity correlates with AR expression in a HER2-dependent manner and serves as a better prognostic factor in breast cancer.
Liu D
Cell Oncol (Dordr); 2020 Apr; 43(2):321-333. PubMed ID: 31933152
[TBL] [Abstract][Full Text] [Related]
6. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
[TBL] [Abstract][Full Text] [Related]
7. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
[TBL] [Abstract][Full Text] [Related]
8. Identification of hub genes in AR-induced tamoxifen resistance in breast cancer based on weighted gene co-expression network analysis.
Lu C; Yang Y; Lingmei L; Qiujuan H; Qianru G; Lisha Q; Wenfeng C; Yun N; Peisen Z
Breast Cancer Res Treat; 2023 Jan; 197(1):71-82. PubMed ID: 36334189
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of prolactin receptor expression in breast cancer subtypes].
Kalinina TS; Kononchuk VV; Sidorov SV; Gulyaeva LF
Biomed Khim; 2020 Jan; 66(1):89-94. PubMed ID: 32116231
[TBL] [Abstract][Full Text] [Related]
10. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers.
Tsang JY; Ni YB; Chan SK; Shao MM; Law BK; Tan PH; Tse GM
Ann Surg Oncol; 2014 Jul; 21(7):2218-28. PubMed ID: 24639191
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer.
Zhao L; Niu F; Shen H; Liu X; Chen L; Niu Y
Virchows Arch; 2016 Jun; 468(6):687-96. PubMed ID: 27026268
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW; Lee KS
Ann Oncol; 2011 Aug; 22(8):1755-62. PubMed ID: 21310761
[TBL] [Abstract][Full Text] [Related]
14. Pre-Menopausal Women With Breast Cancers Having High AR/ER Ratios in the Context of Higher Circulating Testosterone Tend to Have Poorer Outcomes.
Rajarajan S; Korlimarla A; Alexander A; Anupama CE; Ramesh R; Srinath BS; Sridhar TS; Prabhu JS
Front Endocrinol (Lausanne); 2021; 12():679756. PubMed ID: 34234742
[TBL] [Abstract][Full Text] [Related]
15. Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.
Phung HT; Nguyen CV; Mai NT; Vu HTN; Pham KH; Tran GL
Technol Cancer Res Treat; 2022; 21():15330338221080941. PubMed ID: 35379053
[No Abstract] [Full Text] [Related]
16. Clinical significance of PDEF factor expression and its relation to androgen receptor in ER
Cao L; Li C; Xu C; Xiang G; Liu F; Liu X; Jiao J; Lv S; Niu Y
Histopathology; 2018 Nov; 73(5):819-831. PubMed ID: 29969155
[TBL] [Abstract][Full Text] [Related]
17. Prohibitin promotes androgen receptor activation in ER-positive breast cancer.
Liu P; Xu Y; Zhang W; Li Y; Tang L; Chen W; Xu J; Sun Q; Guan X
Cell Cycle; 2017 Apr; 16(8):776-784. PubMed ID: 28272969
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.
Vera-Badillo FE; Templeton AJ; de Gouveia P; Diaz-Padilla I; Bedard PL; Al-Mubarak M; Seruga B; Tannock IF; Ocana A; Amir E
J Natl Cancer Inst; 2014 Jan; 106(1):djt319. PubMed ID: 24273215
[TBL] [Abstract][Full Text] [Related]
19. Androgen Receptor Expression and Bicalutamide Antagonize Androgen Receptor Inhibit β-Catenin Transcription Complex in Estrogen Receptor-Negative Breast Cancer.
Huang R; Han J; Liang X; Sun S; Jiang Y; Xia B; Niu M; Li D; Zhang J; Wang S; Wei W; Liu Q; Zheng W; Zhang G; Song Y; Panga D
Cell Physiol Biochem; 2017; 43(6):2212-2225. PubMed ID: 29069648
[TBL] [Abstract][Full Text] [Related]
20. Hormone receptors in breast cancer: more than estrogen receptors.
Lamb CA; Vanzulli SI; Lanari C
Medicina (B Aires); 2019; 79(Spec 6/1):540-545. PubMed ID: 31864223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
